Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

137

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Disease
Tuberculosis, Pulmonary
Tuberculosis
Multi Drug Resistant Tuberculosis
Drug Sensitive Tuberculosis
Drug-resistant Tuberculosis
Mycobacterium Tuberculosis Infection

Interventions

DRUG: TBAJ-876 suspension
DRUG: Placebo suspension
DRUG: TBAJ-876 100 mg tablet
DRUG: TBAJ-876 25 mg tablet

Sponsor

Global Alliance for TB Drug Development